[go: up one dir, main page]

AR110236A1 - Conjugados de vmen-antígeno y uso de los mismos - Google Patents

Conjugados de vmen-antígeno y uso de los mismos

Info

Publication number
AR110236A1
AR110236A1 ARP170103286A ARP170103286A AR110236A1 AR 110236 A1 AR110236 A1 AR 110236A1 AR P170103286 A ARP170103286 A AR P170103286A AR P170103286 A ARP170103286 A AR P170103286A AR 110236 A1 AR110236 A1 AR 110236A1
Authority
AR
Argentina
Prior art keywords
vmen
conjugates
antigen
same
immunization
Prior art date
Application number
ARP170103286A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR110236A1 publication Critical patent/AR110236A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/075Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La tecnología propuesta se encuentra en el ámbito de la conjugación de vesículas de membrana externa nativas (VMEn), extraídas sin detergente, con antígenos para formar conjugados de VMEn-enlazador-antígeno, que son particularmente útiles para composiciones inmunogénicas e inmunización; también se proporcionan procedimientos para la preparación y el uso de tales conjugados.
ARP170103286A 2016-11-25 2017-11-24 Conjugados de vmen-antígeno y uso de los mismos AR110236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1619949.9A GB201619949D0 (en) 2016-11-25 2016-11-25 nOMV-antigen conjugated compounds and use thereof

Publications (1)

Publication Number Publication Date
AR110236A1 true AR110236A1 (es) 2019-03-06

Family

ID=58073117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103286A AR110236A1 (es) 2016-11-25 2017-11-24 Conjugados de vmen-antígeno y uso de los mismos

Country Status (2)

Country Link
AR (1) AR110236A1 (es)
GB (1) GB201619949D0 (es)

Also Published As

Publication number Publication date
GB201619949D0 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
BR112019010625A2 (pt) conjugado imunogênico, processo para preparar o conjugado imunogênico, nomv-ligante intermediário, usos do mesmo e de nomv, composição imunogênica, e, vacina.
MX2022014980A (es) Conjugados de polipeptido-antigeno con aminoacidos no naturales.
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
BR112019010227A2 (pt) conjugado imunogênico, processo para preparação de conjugado imunogênico, composição imunogênica, vacina, e, uso de nomv
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
CL2018002792A1 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos.
MX2019004690A (es) Constructos de anticuerpos.
CL2015002157A1 (es) Una composición inmunogenica que comprende: un sacárido capsular pneumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antígeno de proteína de unión a factor h (fhbp) menincocócico, pero sin incluir vesículas de membrana meningocócica; metodo de preparación de la composición
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
AR130778A2 (es) Vacunas de meningococos
AR076106A1 (es) Anticuerpos anti-cd40 y usos de los mismos
MX2018015361A (es) Formulacion de vacuna contra el vih.
UY36006A (es) Construcciones de proteína uspa2 y usos de las mismas.
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
CL2016002142A1 (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CL2019000655A1 (es) Nuevo sitio de inserción orf70 de ehv.
CO2021012294A2 (es) Composiciones de lawsonia intracellularis y métodos de uso de las mismas
CL2019000705A1 (es) Nuevos promotores.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR110236A1 (es) Conjugados de vmen-antígeno y uso de los mismos
PE20160174A1 (es) Composiciones vacunales bivalentes y su uso para la terapia de tumores
CL2018000155A1 (es) Composiciones de adyuvante liposomal
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
AR088908A1 (es) Vacuna

Legal Events

Date Code Title Description
FB Suspension of granting procedure